| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Imaging, Diagnosis, Prognosis |
Authors' Affiliations: Departments of 1 Urology, 2 Immunology, 3 Pathology, and 4 Health Sciences Research, Mayo Clinic, Rochester, Minnesota
Requests for reprints: Eugene D. Kwon, Department of Urology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905. Phone: 507-284-5365; Fax: 507-284-1637; E-mail: kwon.eugene{at}mayo.edu.
Purpose: Regulatory T cells (Tregs) have been implicated as inhibitors of antitumoral immunity, and evidence suggests that elimination of Tregs may augment natural and pharmacologic immunity. We tested for the presence of putative Tregs within renal cell carcinoma (RCC) tumors.
Experimental Design: We identified 170 patients who underwent radical or partial nephrectomy for clear cell RCC between 2000 and 2002. Specimens were stained with anti-CD4, anti-CD25, and anti-Foxp3 antibodies and examined using confocal microscopy. Associations of CD4+CD25+Foxp3 and CD4+CD25+Foxp3+ T cells with death from RCC were evaluated using Cox proportional hazards regression models.
Results: At last follow-up, 46 of 170 patients had died; of these, 37 died from RCC at a median of 1.4 years following nephrectomy (range, 0-4.4). Among the 124 remaining patients, median follow-up was 3.7 years (range, 0-5.7). Forty-three (25.3%) tumors harbored CD4+CD25+Foxp3+ T cells. The presence of Foxp3+ T cells was not significantly associated with RCC death univariately. One hundred forty-three (84.1%) tumors harbored CD4+CD25+Foxp3 T cells. The indicator for
10% CD4+CD25+Foxp3 T cells was significantly associated with RCC death univariately [risk ratio (RR), 2.60; 95% confidence interval (95% CI), 1.35-4.98; P = 0.004], after adjusting for tumor B7-H1 expression (RR, 2.53; 95% CI, 1.32-4.85; P = 0.005) and lymphocytic infiltration (RR, 2.53; 95% CI, 1.32-4.87; P = 0.005).
Conclusions: Increased presence of CD4+CD25+Foxp3+ T cells was not significantly associated with RCC death. In contrast, CD4+CD25+Foxp3 T cells, which may represent a unique set of Tregs or activated helper T cells, was significantly associated with outcome.
This article has been cited by other articles:
![]() |
M. Gobert, I. Treilleux, N. Bendriss-Vermare, T. Bachelot, S. Goddard-Leon, V. Arfi, C. Biota, A. C. Doffin, I. Durand, D. Olive, et al. Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome Cancer Res., March 1, 2009; 69(5): 2000 - 2009. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. K. Jensen, F. Donskov, M. Nordsmark, N. Marcussen, and H. von der Maase Increased Intratumoral FOXP3-positive Regulatory Immune Cells during Interleukin-2 Treatment in Metastatic Renal Cell Carcinoma Clin. Cancer Res., February 1, 2009; 15(3): 1052 - 1058. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Abou-Ghazal, D. S. Yang, W. Qiao, C. Reina-Ortiz, J. Wei, L.-Y. Kong, G. N. Fuller, N. Hiraoka, W. Priebe, R. Sawaya, et al. The Incidence, Correlation with Tumor-Infiltrating Inflammation, and Prognosis of Phosphorylated STAT3 Expression in Human Gliomas Clin. Cancer Res., December 15, 2008; 14(24): 8228 - 8235. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Finke, B. Rini, J. Ireland, P. Rayman, A. Richmond, A. Golshayan, L. Wood, P. Elson, J. Garcia, R. Dreicer, et al. Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients Clin. Cancer Res., October 15, 2008; 14(20): 6674 - 6682. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Heimberger, M. Abou-Ghazal, C. Reina-Ortiz, D. S. Yang, W. Sun, W. Qiao, N. Hiraoka, and G. N. Fuller Incidence and Prognostic Impact of FoxP3+ Regulatory T Cells in Human Gliomas Clin. Cancer Res., August 15, 2008; 14(16): 5166 - 5172. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Kavanagh, S. O'Brien, D. Lee, Y. Hou, V. Weinberg, B. Rini, J. P. Allison, E. J. Small, and L. Fong CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion Blood, August 15, 2008; 112(4): 1175 - 1183. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |